Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 65


A comprehensive function analysis of LMO2 in different breast cancer subtypes.

Liu Y, Yuan M, Wu C, Zhu T, Sun W.

Oncotarget. 2017 Dec 21;9(10):8911-8926. doi: 10.18632/oncotarget.23542. eCollection 2018 Feb 6.


LMO2 is required for TAL1 DNA binding activity and initiation of definitive haematopoiesis at the haemangioblast stage.

Stanulovic VS, Cauchy P, Assi SA, Hoogenkamp M.

Nucleic Acids Res. 2017 Sep 29;45(17):9874-9888. doi: 10.1093/nar/gkx573.


Activation of the <i>LMO2</i> oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia.

Rahman S, Magnussen M, León TE, Farah N, Li Z, Abraham BJ, Alapi KZ, Mitchell RJ, Naughton T, Fielding AK, Pizzey A, Bustraan S, Allen C, Popa T, Pike-Overzet K, Garcia-Perez L, Gale RE, Linch DC, Staal FJT, Young RA, Look AT, Mansour MR.

Blood. 2017 Jun 15;129(24):3221-3226. doi: 10.1182/blood-2016-09-742148. Epub 2017 Mar 7.


LMO2 promotes tumor cell invasion and metastasis in basal-type breast cancer by altering actin cytoskeleton remodeling.

Liu Y, Wang Z, Huang D, Wu C, Li H, Zhang X, Meng B, Li Z, Zhu T, Yang S, Sun W.

Oncotarget. 2017 Feb 7;8(6):9513-9524. doi: 10.18632/oncotarget.13434.


LMO2 attenuates tumor growth by targeting the Wnt signaling pathway in breast and colorectal cancer.

Liu Y, Huang D, Wang Z, Wu C, Zhang Z, Wang D, Li Z, Zhu T, Yang S, Sun W.

Sci Rep. 2016 Oct 25;6:36050. doi: 10.1038/srep36050.


LMO2 and IL2RG synergize in thymocytes to mimic the evolution of SCID-X1 gene therapy-associated T-cell leukaemia.

Ruggero K, Al-Assar O, Chambers JS, Codrington R, Brend T, Rabbitts TH.

Leukemia. 2016 Sep;30(9):1959-62. doi: 10.1038/leu.2016.116. Epub 2016 May 12. No abstract available.


High expression of LMO2 predicts a favorable outcome in adult patients with BCR/ABL negative B-cell acute lymphoblastic leukemia.

Aly RM, Taalab MM, Abdsalam EM, Elyamany OH, Hasan OE.

Oncol Lett. 2016 Mar;11(3):1917-1922. Epub 2016 Jan 19.


The LMO2 oncogene regulates DNA replication in hematopoietic cells.

Sincennes MC, Humbert M, Grondin B, Lisi V, Veiga DF, Haman A, Cazaux C, Mashtalir N, Affar el B, Verreault A, Hoang T.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1393-8. doi: 10.1073/pnas.1515071113. Epub 2016 Jan 13.


LMO2 Oncoprotein Stability in T-Cell Leukemia Requires Direct LDB1 Binding.

Layer JH, Alford CE, McDonald WH, Davé UP.

Mol Cell Biol. 2015 Nov 23;36(3):488-506. doi: 10.1128/MCB.00901-15. Print 2016 Feb 1.


The LMO2 -25 Region Harbours GATA2-Dependent Myeloid Enhancer and RUNX-Dependent T-Lymphoid Repressor Activity.

Bonadies N, Göttgens B, Calero-Nieto FJ.

PLoS One. 2015 Jul 10;10(7):e0131577. doi: 10.1371/journal.pone.0131577. eCollection 2015.


LMO2 at 25 years: a paradigm of chromosomal translocation proteins.

Chambers J, Rabbitts TH.

Open Biol. 2015 Jun;5(6):150062. doi: 10.1098/rsob.150062. Review.


BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.

Ding J, Dirks WG, Ehrentraut S, Geffers R, MacLeod RA, Nagel S, Pommerenke C, Romani J, Scherr M, Vaas LA, Zaborski M, Drexler HG, Quentmeier H.

Haematologica. 2015 Jun;100(6):801-9. doi: 10.3324/haematol.2014.120048. Epub 2015 Mar 13.


The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells.

Kim SH, Kim EJ, Hitomi M, Oh SY, Jin X, Jeon HM, Beck S, Jin X, Kim JK, Park CG, Chang SY, Yin J, Kim T, Jeon YJ, Song J, Lim YC, Lathia JD, Nakano I, Kim H.

Cell Death Differ. 2015 Sep;22(9):1517-25. doi: 10.1038/cdd.2015.7. Epub 2015 Feb 27.


High frequency of cryptic chromosomal rearrangements involving the LMO2 gene in T-cell acute lymphoblastic leukemia.

Wu L, Xu Y, Wang Q, Ruan C, Drexler HG, Wu D, MacLeod RA, Chen S.

Haematologica. 2015 Jun;100(6):e233-6. doi: 10.3324/haematol.2014.120089. Epub 2015 Feb 14. No abstract available.


Enforced expression of E47 has differential effects on Lmo2-induced T-cell leukemias.

Goodings C, Tripathi R, Cleveland SM, Elliott N, Guo Y, Shyr Y, Davé UP.

Leuk Res. 2015 Jan;39(1):100-9. doi: 10.1016/j.leukres.2014.11.016. Epub 2014 Nov 29.


LMO2 induces T-cell leukemia with epigenetic deregulation of CD4.

Cleveland SM, Goodings C, Tripathi RM, Elliott N, Thompson MA, Guo Y, Shyr Y, Davé UP.

Exp Hematol. 2014 Jul;42(7):581-93.e5. doi: 10.1016/j.exphem.2014.04.010. Epub 2014 May 2.


LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.

Lossos C, Bayraktar S, Weinzierl E, Younes SF, Hosein PJ, Tibshirani RJ, Sutton Posthumus J, DeAngelis LM, Raizer J, Schiff D, Abrey L, Natkunam Y, Lossos IS.

Br J Haematol. 2014 Jun;165(5):640-8. doi: 10.1111/bjh.12801. Epub 2014 Feb 26. Review.


LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways.

Smith S, Tripathi R, Goodings C, Cleveland S, Mathias E, Hardaway JA, Elliott N, Yi Y, Chen X, Downing J, Mullighan C, Swing DA, Tessarollo L, Li L, Love P, Jenkins NA, Copeland NG, Thompson MA, Du Y, Davé UP.

PLoS One. 2014 Jan 21;9(1):e85883. doi: 10.1371/journal.pone.0085883. eCollection 2014.


Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex.

Sewell H, Tanaka T, El Omari K, Mancini EJ, Cruz A, Fernandez-Fuentes N, Chambers J, Rabbitts TH.

Sci Rep. 2014 Jan 10;4:3643. doi: 10.1038/srep03643.

Supplemental Content

Loading ...
Support Center